Melinda Pruis

Melinda Pruis

Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing.

Back to news

More news

Arno de Quaasteniet new member of the board of Hartwig Medical Foundation

Arno de Quaasteniet new member of the board of Hartwig Medical Foundation

21-11-2024

Hartwig Medical Foundation is pleased to announce that as of October 1, 2024, Arno de Quaasteniet (1977) has been appointed …

To study rare cancers, collaboration is key 

To study rare cancers, collaboration is key 

28-02-2025

In honor of Rare Disease Day on February 28th, we spoke with Professor Stefan Fröhling about his research on rare …

Dutch Healthcare Institute approves reimbursement of whole genome sequencing (WGS) for targeted cancer treatment 

Dutch Healthcare Institute approves reimbursement of whole genome sequencing (WGS) for targeted cancer treatment 

15-08-2025

The Dutch National Health Care Institute (Zorginstituut Nederland, ZiNL) has approved the reimbursement of whole genome sequencing (WGS) through the …

Would you like to be kept up to date with new developments?

Sign up for our newsletters

Want to know more about the complete DNA test?

Visit OncoAct.nl